Regeneron Pharmaceuticals has patented a method for treating non-small cell lung cancer (NSCLC) by administering platinum-based chemotherapy with an anti-PD-1 antibody. The treatment is specifically for patients negative for certain mutations and translocations, aiming to increase survival rates. GlobalData’s report on Regeneron Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Regeneron Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Regeneron Pharmaceuticals, Transgenic murine models was a key innovation area identified from patents. Regeneron Pharmaceuticals's grant share as of February 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of non-small cell lung cancer with pd-1 antagonist

Source: United States Patent and Trademark Office (USPTO). Credit: Regeneron Pharmaceuticals Inc

A recently granted patent (Publication Number: US11926668B2) outlines a method for treating non-small cell lung cancer (NSCLC) or increasing the survival of patients with NSCLC. The method involves selecting patients who have tested negative for specific genetic mutations and translocations, and administering platinum-based chemotherapy in combination with an antibody that binds to PD-1. The antibody used in the treatment has specific amino acid sequences for both heavy and light chain complementarity determining regions. The treatment regimen includes administering the antibody concurrently or prior to chemotherapy, with specific dosage ranges and intervals mentioned in the claims.

Furthermore, the patent details additional therapeutic options that can be combined with the treatment, such as other inhibitors, antibodies, chemotherapeutic agents, and immunotherapies. The method aims to delay tumor growth, prevent recurrence, and improve overall survival outcomes for NSCLC patients. The patent also specifies the use of a particular antibody, cemiplimab, for intravenous administration every three weeks at a dose of 350 mg. Overall, the patent provides a comprehensive approach to treating NSCLC in patients who meet specific criteria, offering a potentially effective treatment option for this challenging disease.

To know more about GlobalData’s detailed insights on Regeneron Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies